Catamaran Bio

Catamaran Bio

  • Founded: 2020
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Breast cancer, gastric cancer
  • Drug types: ONC
  • Lead product: CAT-179
  • Product link:
  • Funding: $42M A Nov 2020

job board

Short description:

CAR-Natural Killer Cell Therapies

Drug notes:

CAT-248 RD renal cell carcinoma; undisclosed RD solid tumors

Long description:

Catamaran Bio is developing off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell therapies to address a broad range of cancers. NK cells are critical components of the immune system that possess natural cancer-fighting properties. Catamaran is using synthetic biology and non-viral cell engineering to create novel CAR-NK cells that are capable of treating solid tumors by combining new functional attributes with their inherent cancer-killing properties. To achieve this, Catamaran developed TAILWIND®, their proprietary suite of technologies that CAR-NK cell therapy development and manufacturing for multiple cancer types. Catamaran’s lead candidate, CAT-248, has been engineered with four functional modifications and will be tested in clinical studies for renal cell carcinoma.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy